US 12,129,291 B2
Anti-GPC3 antibody
Koji Tamada, Yamaguchi (JP); Yukimi Sakoda, Yamaguchi (JP); Tetsuya Nakatsura, Chiba (JP); and Keigo Saito, Chiba (JP)
Assigned to Yamaguchi University, Yamaguchi (JP); National Cancer Center, Tokyo (JP); and Noile-Immune Biotech, Inc., Tokyo (JP)
Filed by Yamaguchi University, Yamaguchi (JP); National Cancer Center, Tokyo (JP); and Noile-Immune Biotech, Inc., Tokyo (JP)
Filed on Jun. 15, 2023, as Appl. No. 18/335,477.
Application 18/335,477 is a continuation of application No. 16/472,356, granted, now 11,718,663, previously published as PCT/JP2018/000257, filed on Jan. 10, 2018.
Claims priority of application No. 2017-001732 (JP), filed on Jan. 10, 2017.
Prior Publication US 2024/0018224 A1, Jan. 18, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/18 (2006.01); C07K 14/54 (2006.01); C07K 14/725 (2006.01); C07K 16/30 (2006.01); C12N 5/078 (2010.01); C12N 5/0783 (2010.01); G01N 33/68 (2006.01)
CPC C07K 16/18 (2013.01) [C07K 14/5418 (2013.01); C07K 14/7051 (2013.01); C07K 16/303 (2013.01); C12N 5/0634 (2013.01); C12N 5/0636 (2013.01); G01N 33/68 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01)] 15 Claims
 
1. An antibody specifically binding to a human GPC3 (glypican-3)-derived polypeptide consisting of the amino acid sequence represented by SEQ ID NO: 155, wherein the antibody
(1-1) comprises a heavy chain complementarity determining region (CDR) 1 consisting of the amino acid sequence represented by SEQ ID NO: 1, a heavy chain CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 2, and a heavy chain CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 3, and
a light chain CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 4, a light chain CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 5, and a light chain CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 6.